



Rapid Rabbit IgG Quantification using the ValitaTiter Assay

Introduction

Rodents, such as mice and rats, have been the dominant host for antibody production since the discovery of hybridoma technology in the 1970s. However, as researchers expand their knowledge on the immune system of different species, other hosts have become attractive targets due to their unique characteristics. One such host are rabbits. In contrast to a rodent's immune system, rabbits seem to be able to recognize a much broader diversity of antigens. Additionally, antibodies produced by rabbits have exhibited a significantly higher affinity, specifically against epitopes of human origin, or epitopes known to be non-immunogenic in mice. Disadvantages of rabbits as hosts for antibody production are the increases in project time (due to longer immunization regimens) and cost (due to lengthier and more complex husbandry requirements) when compared to rodent hosts. As such, the accurate, rapid, and cost-effective measurement of rabbit IgG throughout antibody development is essential and can aid in the mitigation of these disadvantages. This application note demonstrates the use of the ValitaTiter assay as a high-throughput, rapid and precise tool for quantifying rabbit IgG.

ValitaTiter Assay

The ValitaTiter assay is a rapid, high-throughput IgG quantification assay which uses fluorescence polarization (FP) for detection. The assay relies on interactions between a fluorescently labeled IgG Fc-specific probe and the Fc of an IgG. FP effectively analyzes changes in the size of molecules, given that smaller molecules tumble more rapidly than larger ones in solution. The rotation of the molecules between absorption and emission of the photon has the effect of 'twisting' the polarization of the light. When the fluorescently labeled IgG-binding peptide is unbound, it tumbles rapidly and depolarizes the light more than when it is bound to an IgG (which is ~20 times larger). Therefore, FP is measured by exciting the solution with plane polarized light and measuring the intensity of light emitted in the plane parallel to the exciting light (polarized proportion) and perpendicular to the exciting light (depolarized portion). The FP is expressed as a normalized difference of these two intensities, which is typically in millipolarization units (mP).

Assay Principle




FIGURE 1. ValitaTiter assay principle. Small, unbound molecules rotate rapidly in solution (top), while large, bound molecules rotate slowly (bottom).

Materials and Method

Materials

- ValitaTiter assay, catalogue number: VAL003, detection range: 2.5 - 100 mg/L
- CD CHO medium (Gibco™, Catalogue No. 10743)
- BMG Labtech PHERAstar Multimode plate reader
- Monoclonal Rabbit IgG Isotype Control Antibody (LSBio, Catalogue No. LS-C742137)
- Normal Polyclonal Rabbit IgG Control (SinoBiological Catalogue No. CR1)
- ThermoFisher Finnpiptette F2 Pipettes (Catalogue No. 10413865, 1187735, 11887351, 4662060)
- Starlab TipOne Tips (0.5 - 200 µL Catalogue No. S1111-1700) (1000 µL Catalogue No. S1111-6811)

Method

BMG Labtech PHERAstar settings

Optic settings	Fluorescence Polarization, endpoint
	Optic module FP 485 520 520
	Focus and gain optimized from most fluorescent well (0 mg/L)
	70 mP target mP for gain
General settings	200 flashes per well
	0.5 s settling time

Monoclonal Rabbit IgG

Monoclonal rabbit IgG standard was reconstituted in distilled H₂O to a concentration of 4 mg/mL as per the manufacturer's instructions. Dilutions were performed in CD-CHO media to prepare an 8-point standard curve ranging from 100 mg/L to 0 mg/L. Test samples were prepared from the 4 mg/mL stock solution diluted in CD-CHO media.


Polyclonal Rabbit IgG

Polyclonal rabbit IgG was received from the manufacturers at a concentration of 1 mg/L in PBS pH 7.4. Serial dilutions were performed in CD-CHO media to prepare an 8-point standard curve ranging from 100 mg/L to 0 mg/L. Test samples were prepared from the 1 mg/mL stock solution diluted in CD-CHO media.

The assay protocol was performed using single and multichannel pipettes as follows:

Assay Procedure

1. 60 µl of cell culture media was added to each well to reconstitute the Fc-specific probe (pre-dried onto the surface of the ValitaTiter plate)
2. 60 µl of each standard/sample was then added into appropriate wells of the 96-well plate
3. A multichannel pipette was used to mix each well 3 times prior to a 5-minute incubation in the dark
4. Post incubation, the plate was measured using FP



1. ValitaTiter plate is coated with an IgG specific binding peptide
2. IgG in test sample forms complex with the binding peptide
3. IgG concentration is measured using FP on a plate reader

FIGURE 2. Assay schematic of ValitaTiter assay for IgG quantification using fluorescence polarization. 1. Each well of the plate is pre-coated with a fluorescently labeled IgG Fc-specific probe. 2. An IgG sample binds to the probe. 3. Binding is measured using fluorescence polarization.

Results

An investigation was carried out to assess the use of the ValitaTiter assay to accurately detect and quantify rabbit IgG. Both monoclonal antibodies (mAb) and polyclonal antibodies (pAb) were investigated. As this is a relative quantification method, to enhance the accuracy of prediction, it is important to ensure that the molecule deployed as the standard is homogeneous to the test samples. In this example, when quantifying mAb test samples, a mAb standard curve was used for interpolation. An eight-point standard curve (0 - 100 mg/L) for each molecule was prepared in duplicate and analyzed using the ValitaTiter assay. Alongside standard curve generation, samples of known concentration were interpolated against the standard curve and accuracy bias assessed.

A linear regression fit, whereby the concentration of IgG [mg/L] was plotted on the x-axis and Raw FP on the y-axis [Figure 3], was identified as the best fit for the mAb standard curve samples. The equation of the line was utilized to interpolate the concentration of mAb test samples by substituting the output Raw FP value for y and solving for x.




Figure 3. Rabbit monoclonal IgG ValitaTiter assay standard curve plotted using a linear fit ($R^2 = 0.998$). Error bars show standard deviation of replicates.

The ValitaTiter assay accurately interpolated the known concentration of test samples with a % accuracy bias versus the known absolute concentration of $\leq 8\%$, standard deviation of ≤ 2 mP, and an intra-plate coefficient of variation of $\leq 2\%$, passing all typical acceptance criteria [Table 1]. Figure 4 demonstrates that output data generated using the ValitaTiter assay correlates well with known absolute values, with an R^2 of 0.99.

Known IgG concentration in sample (mg/L)	Interpolated concentration rep1 (mg/L)	Interpolated concentration rep2 (mg/L)	Interpolated concentration rep3 (mg/L)	Average (mg/L)	Std. deviation [mP]	Accuracy bias (%)	Coefficient of variation (%)
90	93.5	92.3	90.3	92.0	1.55	-2	0.999
60	64.3	63.8	61.1	63.0	1.63	-5	1.275
55	58.0	58.1	56.1	57.4	1.05	-4	0.856
40	39.7	39.0	38.8	38.8	0.92	+3	0.874
25	25.9	25.1	24.8	25.3	0.55	-1	0.596
12.5	13.3	13.6	13.4	13.5	0.14	-8	0.173
10	10.7	10.6	9.6	8.8	0.58	-3	0.745

Table 1. Summary of output data from the use of ValitaTiter assay for quantifying mAb test samples of known concentration.




Figure 4. ValitaTiter assay predicted IgG concentrations plotted against actual concentrations for rabbit monoclonal IgG ($R^2 = 0.9973$).

A 2nd order polynomial fit was identified as the optimum fit for the pAb standard curve samples. Here, the concentration of IgG [mg/L] is plotted on the y-axis and the Raw FP on the x-axis [Figure 5]. The equation of the line was utilized to interpolate the concentration of pAb test samples by substituting the output Raw FP value for x and solving for y. The assay accurately interpolated the known concentration of test samples with a % accuracy bias versus the known absolute concentration of $\leq 10\%$, standard deviation of ≤ 2 mP, and an intra-plate coefficient of variation of $\leq 2\%$ [Table 2]. Figure 6 demonstrates that output data generated using the ValitaTiter assay correlates well with absolute values, with an R^2 of 0.99.




Figure 5. Rabbit polyclonal IgG ValitaTiter assay standard curve plotted using a poly-2 fit ($R^2 = 0.9941$). Error bars show standard deviation of replicates.

Known IgG concentration in sample (mg/L)	Interpolated concentration rep1 (mg/L)	Interpolated concentration rep2 (mg/L)	Interpolated concentration rep3 (mg/L)	Average (mg/L)	Std. deviation [mP]	Accuracy bias (%)	Coefficient of variation (%)
90	84.1	84.1	83.9	84.1	0.11	+7	0.061
60	66.8	65.4	65.5	65.9	0.96	-10	0.623
55	57.4	56.2	55.5	56.4	1.15	-3	0.809
40	39.5	39.5	40.1	39.7	0.4	+1	0.331
25	24.1	24.2	24	24.1	0.13	+4	0.133
12.5	11.5	12.0	11.4	11.6	0.45	+7	0.540
10	9.0	9.6	10.0	9.5	0.71	+5	0.882

Table 2. ValitaTiter is capable of accurate interpolation of polyclonal rabbit IgG samples using a standard curve.




Figure 6. ValitaTiter assay predicted IgG concentrations plotted against actual concentrations for rabbit polyclonal IgG ($R^2 = 0.9917$).

Conclusions

The ValitaTiter assay is capable of robust, accurate measurement of rabbit IgG standards and samples. The assay allows for high-throughput, direct, rapid and precise quantification of crude rabbit IgG samples at various stages of development.

Abbreviations

FP Fluorescence polarization

mP Millipolarization units

IgG Immunoglobulin G

mAb Monoclonal antibody

pAb Polyclonal antibody

About the Authors

Dr. Anna Boland is a Product Development Scientist at ValitaCell Ltd. She studied Molecular Medicine at Trinity College Dublin and has a PhD in Medicine from Queen's University Belfast.

Dr. Hannah Byrne is the Head of Biological Sciences at ValitaCell Ltd. She studied Analytical Science at Dublin City University and has a PhD in Biochemistry. Valitacell is a growing biotech company developing innovative technologies to aid and improve drug discovery and development.



Valita, ValitaTiter and the ValitaCell logo are trademarks or registered trademarks of ValitaCell in the United States and other countries. ValitaCell is a Beckman Coulter Company. This method is for demonstration only, and is not validated by Beckman Coulter. Beckman Coulter makes no warranties of any kind whatsoever express or implied, with respect to this protocol, including but not limited to warranties of fitness for a particular purpose or merchantability or that the protocol is non-infringing. All warranties are expressly disclaimed. Your use of the method is solely at your own risk, without recourse to Beckman Coulter. Not intended or validated for use in the diagnosis of disease or other conditions.

© 2023 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.



For Beckman Coulter's worldwide office locations and phone numbers, please visit Contact Us at [beckman.com](https://www.beckman.com)

2022-GBL-EN-100355-v3